First AD

Second AD

Overview of the ROCKstar Study

Video content above is prompted by the following:

Please review data that led to belumosudil’s FDA approval (Jagasia M, et al. 

Efficacy data (duration of effect, need for additional treatments, data on decrease in formation of scar tissue and decrease in immune cell activity, etc).

Safety profile of belumosudil and adverse effect management.

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Optimizing Treatment for Chronic GVHD

Medical experts discuss the data that led to belumosudil’s FDA approval. 